Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12575149 | 1.00 | BHMT (0.42) | BHMTCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL14445570 | 0.90 | BHMT (0.48) | BHMTCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL3392036 | 0.89 | ALDH1A1 (0.38) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL258152 | 0.86 | SLC22A6 (0.50) | BHMTCACNA2D1CACNB3CACNA1CPGR | |
| Acetamide SCHEMBL4103797 | 0.83 | LMNA (0.47) | CACNA2D1CACNB3CACNA1CECE1LMNA | |
| SCHEMBL11112412 | 0.83 | SLC22A6 (0.47) | BHMTCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL10902055 | 0.83 | SLC22A6 (0.47) | BHMTCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL14109598 | 0.83 | SLC22A6 (0.47) | BHMTCACNA2D1CACNB3CACNA1CPGR | |
| Ethane SCHEMBL5968227 | 0.83 | SLC22A6 (0.47) | BHMTCACNA2D1CACNB3CACNA1CPGR | |
| Ammonia Solution, Strong SCHEMBL28582304 | 0.83 | TDP1 (0.53) | BHMTCACNA2D1CACNB3CACNA1CPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3367999-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | The Procter and Gamble Company (US) | 2018-09-05 | — | — | EP | claimed |
| US-20170121633-A1 | Fragrance Compositions Comprising Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2017-05-04 | — | — | US | claimed |
| WO-2017075299-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | THE PROCTER & GAMBLE COMPANY (US) | 2017-05-04 | — | — | WO | claimed |
| WO-2024017969-A1 | SILANE-TERMINATED POLYMERS | MERZ + BENTELI AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017972-A1 | SILANE-TERMINATED POLYMERS | MERZ + BENTELI AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023048554-A1 | METHOD FOR EARLY DIAGNOSIS OF GESTATIONAL DIABETES | Universidad Nacional Autónoma de México (MX) | 2023-03-30 | — | — | WO | disclosed |
| EP-3367999-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | The Procter and Gamble Company (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075299-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | THE PROCTER & GAMBLE COMPANY (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170121633-A1 | Fragrance Compositions Comprising Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2017-05-04 | — | — | US | disclosed |
| US-9346755-B2 | Kinetic resolution | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN TRINITY COLLEGE, UNIVERSITY OF DUBLIN (IE) | 2016-05-24 | — | — | US | disclosed |
| US-9346755-B2 | Kinetic resolution | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN TRINITY COLLEGE, UNIVERSITY OF DUBLIN (IE) | 2016-05-24 | — | — | US | disclosed |
| US-20150073170-A1 | KINETIC RESOLUTION | The Provost, Fellows, Foundation Scholars, and the Other Members of the Board, of the College of the (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073170-A1 | KINETIC RESOLUTION | The Provost, Fellows, Foundation Scholars, and the Other Members of the Board, of the College of the (IE) | 2015-03-12 | — | — | US | disclosed |
| US-8946429-B2 | Kinetic resolution | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF THE BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2015-02-03 | — | — | US | disclosed |
| US-8946429-B2 | Kinetic resolution | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF THE BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2015-02-03 | — | — | US | disclosed |
| US-20120277437-A1 | KINETIC RESOLUTION | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY (IE) | 2012-11-01 | — | — | US | disclosed |
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| WO-2011070028-A1 | KINETIC RESOLUTION | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2011-06-16 | — | — | WO | disclosed |
| EP-2332895-A1 | Kinetic Resolution | The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin (IE) | 2011-06-15 | — | — | EP | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073170-A1 | KINETIC RESOLUTION | SPR, ADH5, ADH1C | BHMT 70/4885CACNA2D1 4724/4885CACNB3 2975/4885 |
| US-20170121633-A1 | Fragrance Compositions Comprising Ionic Liquids | CUTA, TRPA1, POLR1C | BHMT 3013/4885CACNA2D1 3612/4885CACNB3 2014/4885 |
| US-20120277437-A1 | KINETIC RESOLUTION | SPR, ADH5, ADH1C | BHMT 70/4885CACNA2D1 4724/4885CACNB3 2975/4885 |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | BHMT 1434/4885CACNA2D1 2964/4885CACNB3 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.